ClinicalTrials.gg
CompletedNCT00686374Updated Jul 2, 2018Results posted

Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806

A Phase 3 interventional study of Adalimumab in Crohn's Disease, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-07-02.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
7 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
24th of 42
100 · median 143
Started
2008
with 1 other
Phase 3
22 of 42
none open now
Registered
13th of 42
by date
Lead sponsor
2 of 42
AbbVie (prior sponsor, Abbott)

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 24th largest by enrollment, is one of 2 that started in 2008, is one of 22 in phase 3, and was the 13th registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 7 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

This was a multicenter, open-label study to evaluate the human monoclonal anti-TNF-α antibody adalimumab as an effective therapy for maintaining clinical response in pediatric participants with Crohn's disease (CD) and to gather long-term safety and tolerability data in this population. Participants were allowed to enroll in the study if they participated in and successfully completed Study M06-806 (NCT00409682) through Week 52.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's Disease
  • adalimumab
04

Who can participate

Ages eligible
7 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have successfully enrolled in and completed Study M06-806 through Week 52.
  • Participant must have been a responder at any time point during the M06-806 study (defined as having achieved at least a 15-point reduction in the Pediatric Crohn's Disease Activity Index (PCDAI) from Baseline).
  • If female, participants who were sexually active and of were to be practicing an approved method of throughout the study and for 150 days after study drug administration. Examples of approved methods of birth control included the following:

    1. Condoms, sponge, foam, jellies, diaphragm or intrauterine device (IUD)
    2. Oral, parenteral or intravaginal contraceptives
    3. A vasectomized partner
  • Participant of legal age, parent or legal guardian, as required, voluntarily signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved form, after the nature of the study was explained and the participant of legal age, participant's parent, or legal guardian, as required, had the opportunity to ask questions. Participants were to be included in all discussions, and if required, their signature on an assent form was to be obtained.
  • Parent or legal guardian of participant who was not of legal age, as required, must have been willing to actively supervise storage and administration of study drug and to ensure that the time of each dose was accurately recorded in the participant's diary.
  • Participants of legal age, must have been willing to actively store, administer, and accurately record study drug administration in the participant diary.
  • Participant was judged to be in acceptable medical condition, as determined by the Principal Investigator based upon results of clinical and laboratory evaluations done throughout the preceding Crohn's disease study M06-806.

Exclusion criteria

Exclusion Criteria:

  • For any reason, the participant was considered by the Investigator to be an unsuitable candidate for continuing therapy in the M06-807 study.
  • Participant had abnormal laboratory or other test results that in the opinion of the Investigator would make the participant unsuitable to participate in this study.
  • History of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma in-situ of the cervix.
  • History of listeriosis, histoplasmosis, chronic or active infection, (HIV) infection, any immunodeficiency syndrome, central nervous system (CNS) demyelinating disease or active TB (receiving treatment or not receiving treatment). Ongoing severe infections such as sepsis and opportunistic infections were exclusionary.
  • Participant with known, symptomatic obstructive strictures.
  • Participant who was planning surgical bowel resection at any time point while enrolled in the study.
  • Participant who had short bowel syndrome as determined by the Investigator.
  • Participant who was receiving total parenteral nutrition (TPN).
  • Participant who was unwilling to discontinue growth hormone prior to the first dose of open-label study drug at the Baseline visit of M06-807.
  • Female participant who was pregnant or currently breastfeeding.
  • Participant with a history of drug or alcohol abuse in the last year.
  • Participant with a poorly controlled medical condition such as: uncontrolled diabetes, recurrent infections, unstable ischemic heart disease, moderate to severe heart failure, recent cerebrovascular accidents or any other condition which, in the opinion of the Investigator or the Sponsor, would put the participant at risk by participation in the protocol.
  • Participant with any prior exposure to Tysabri (natalizumab).
  • Participant with a known to the of adalimumab as stated in the label.
  • Participant with a previous history of dysplasia of the gastrointestinal tract.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Any adalimumab

    Adalimumab was administered via subcutaneous injection. Dosage was based on body weight and clinical status, and ranged from 10, 20, or 40 mg every other week to 20 or 40 mg every week.

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Participants who enrolled into the study from blinded therapy in Study M06-806 received open-label (OL) therapy at a dose dependent on their body weight. Participants weighing ≥ 40 kg received 40 mg of adalimumab every other week (eow), and those who weighed \< 40 kg received 20 mg of adalimumab eow. Starting at Week 8, participants who had a disease flare may have been switched to every week (ew) treatment at the same dose of adalimumab received while on eow treatment. Participants who enrolled from OL therapy in Study M06-806 continued to receive the same dose they were receiving (i.e., 40 mg ew or 20 mg ew) at the Week 52 visit of Study M06-806. Adalimumab dose could have been decreased to the next lower treatment level for those with body weight changes. Participants who responded to treatment may have also had their dosage frequency decreased from ew to eow dosing, as well as a decrease in dosage.

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission Over Time

    Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

    Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408

  2. Number of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score Over Time

    Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. The baseline PCDAI value was defined as the last non-missing value on or before the date of the first dose of study drug during Study M06-806. Clinical response was defined as a PCDAI ≥ 15 points lower than the Study M06-806 baseline PCDAI value.

    Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408

Secondary outcomes

  1. Number of Participants Who Were in Crohn's Disease Activity Index (CDAI) Clinical Remission Over Time

    The CDAI includes 8 variables encompassing both subject-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept track of daily symptoms on a diary card, and the daily symptom scores were summed for the week. Each item in the CDAI is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. The scale for the score is as follows: \< 150 to indicate remission, 150 - 219 to define mildly active disease, 220 - 450 to define moderately active disease, and \> 450 to define severely active disease. A CDAI was calculated at each visit for participants who were age 13 or older at Study M06-806 entry. The Study M06-806 Week 52 visit served as the baseline visit for this study.

    Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408

  2. Number of Participants Who Were in Crohn's Disease Activity Index (CDAI) Clinical Response Over Time

    The CDAI includes 8 variables: subject-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight). Participants kept track of symptoms on a diary card, and scores were summed for the week. Each item is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. Scale: \< 150 (remission), 150 - 219 (mildly active disease), 220 - 450 (moderately active disease), and \> 450 (severely active disease). A CDAI was calculated at each visit for participants ≥ 13 yrs old at M06-806 entry. Clinical response was defined as a decrease from M06-806 Baseline CDAI value of ≥ 70 pts. The M06-806 Baseline value was defined as the last non-missing value on or before the date of the 1st dose of study drug in M06-806.

    Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408

  3. Number of Participants in Steroid-free Pediatric Crohn's Disease Activity Index (PCDAI) Remission Over Time

    Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

    Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384

  4. Number of Participants in Steroid-free Crohn's Disease Activity Index (CDAI) Remission Over Time

    The CDAI includes 8 variables encompassing subject-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. Participants kept track of daily symptoms on a diary card, and the scores were summed for the week. Each item in the CDAI is assigned a specific weight, and the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. The scale for the score is as follows: \< 150 (remission), 150 - 219 (mildly active disease), 220 - 450 (moderately active disease), and \> 450 (severely active disease). A CDAI was calculated at each visit for subjects ≥ 13 years old at M06-806 entry. CDAI corticosteroid-free remission was defined as discontinued use at least 90 consecutive days prior to the respective visit and a CDAI \< 150 at that visit.

    Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384

  5. Mean Change From Baseline in Pediatric Crohn's Disease Activity Index (PCDAI) Over Time

    Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. The baseline value was defined as the last non-missing value on or before the date of the first dose of study drug in Study M06-806. Negative changes indicate reductions (improvement) in disease activity.

    Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384

  6. Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) Over Time

    The CDAI includes 8 variables: participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. Participants kept track of daily symptoms on a diary card, and the scores were summed for the week. Each item in the CDAI is assigned a specific weight, and the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. The scale for the score is as follows: \< 150 (remission), 150 - 219 (mildly active disease), 220 - 450 (moderately active disease) and \> 450 (severely active disease). A CDAI was calculated at each visit for those who were ≥ 13 years old at Study M06-806 entry. The baseline value was defined as the last non-missing value on or before the date of the first dose of study drug in Study M06-806. Negative changes indicate reductions (improvement) in disease activity.

    Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384

07

Results

Posted Apr 20, 2018

Participant flow

Participant flow — Overall Study
MilestoneAny Adalimumab
Started100
Completed39
Not completed61
Withdrew: Lack of efficacy10
Withdrew: Adverse event8
Withdrew: Withdrew consent5
Withdrew: Lost to follow-up1
Withdrew: Missing reason33
Withdrew: Other, not specified4

Outcome measures

PrimaryNumber of Participants Who Achieved Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission Over Time

Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

Time frame:
Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission Over Time
ParticipantsAny Adalimumab
Week 067
Week 465
Week 867
Week 1260
Week 2459
Week 3660
Week 4854
Week 6060
Week 7249
Week 8454
Week 9654
Week 10854
Week 12052
Week 14451
Week 16844
Week 19244
Week 21636
Week 24037
Week 26431
Week 28824
Week 31214
Week 3368
Week 3607
Week 3842
PrimaryNumber of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score Over Time

Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. The baseline PCDAI value was defined as the last non-missing value on or before the date of the first dose of study drug during Study M06-806. Clinical response was defined as a PCDAI ≥ 15 points lower than the Study M06-806 baseline PCDAI value.

Time frame:
Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score Over Time
ParticipantsAny Adalimumab
Week 095
Week 490
Week 892
Week 1287
Week 2488
Week 3682
Week 4874
Week 6076
Week 7272
Week 8469
Week 9672
Week 10870
Week 12065
Week 14464
Week 16853
Week 19252
Week 21646
Week 24043
Week 26435
Week 28828
Week 31215
Week 33610
Week 3608
Week 3842
SecondaryNumber of Participants Who Were in Crohn's Disease Activity Index (CDAI) Clinical Remission Over Time

The CDAI includes 8 variables encompassing both subject-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept track of daily symptoms on a diary card, and the daily symptom scores were summed for the week. Each item in the CDAI is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. The scale for the score is as follows: \< 150 to indicate remission, 150 - 219 to define mildly active disease, 220 - 450 to define moderately active disease, and \> 450 to define severely active disease. A CDAI was calculated at each visit for participants who were age 13 or older at Study M06-806 entry. The Study M06-806 Week 52 visit served as the baseline visit for this study.

Time frame:
Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408
Reported as:
Count of participants · Participants
Number of Participants Who Were in Crohn's Disease Activity Index (CDAI) Clinical Remission Over Time
ParticipantsAny Adalimumab
Week 058
Week 455
Week 858
Week 1253
Week 2454
Week 3652
Week 4848
Week 6049
Week 7247
Week 8446
Week 9645
Week 10845
Week 12042
Week 14440
Week 16835
Week 19231
Week 21627
Week 24026
Week 26423
Week 28817
Week 31215
Week 3368
Week 3607
Week 3841
SecondaryNumber of Participants Who Were in Crohn's Disease Activity Index (CDAI) Clinical Response Over Time

The CDAI includes 8 variables: subject-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight). Participants kept track of symptoms on a diary card, and scores were summed for the week. Each item is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. Scale: \< 150 (remission), 150 - 219 (mildly active disease), 220 - 450 (moderately active disease), and \> 450 (severely active disease). A CDAI was calculated at each visit for participants ≥ 13 yrs old at M06-806 entry. Clinical response was defined as a decrease from M06-806 Baseline CDAI value of ≥ 70 pts. The M06-806 Baseline value was defined as the last non-missing value on or before the date of the 1st dose of study drug in M06-806.

Time frame:
Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408
Reported as:
Count of participants · Participants
Number of Participants Who Were in Crohn's Disease Activity Index (CDAI) Clinical Response Over Time
ParticipantsAny Adalimumab
Week 055
Week 456
Week 856
Week 1251
Week 2452
Week 3653
Week 4848
Week 6048
Week 7245
Week 8447
Week 9645
Week 10847
Week 12040
Week 14441
Week 16834
Week 19233
Week 21628
Week 24028
Week 26424
Week 28818
Week 31215
Week 3369
Week 3607
Week 3841
SecondaryNumber of Participants in Steroid-free Pediatric Crohn's Disease Activity Index (PCDAI) Remission Over Time

Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

Time frame:
Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384
Reported as:
Count of participants · Participants
Number of Participants in Steroid-free Pediatric Crohn's Disease Activity Index (PCDAI) Remission Over Time
ParticipantsAny Adalimumab
Week 023
Week 423
Week 823
Week 1220
Week 2421
Week 3619
Week 4819
Week 6024
Week 7217
Week 8419
Week 9620
Week 10818
Week 12019
Week 14417
Week 16816
Week 19215
Week 21613
Week 24013
Week 26411
Week 2889
Week 3125
Week 3362
Week 3601
SecondaryNumber of Participants in Steroid-free Crohn's Disease Activity Index (CDAI) Remission Over Time

The CDAI includes 8 variables encompassing subject-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. Participants kept track of daily symptoms on a diary card, and the scores were summed for the week. Each item in the CDAI is assigned a specific weight, and the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. The scale for the score is as follows: \< 150 (remission), 150 - 219 (mildly active disease), 220 - 450 (moderately active disease), and \> 450 (severely active disease). A CDAI was calculated at each visit for subjects ≥ 13 years old at M06-806 entry. CDAI corticosteroid-free remission was defined as discontinued use at least 90 consecutive days prior to the respective visit and a CDAI \< 150 at that visit.

Time frame:
Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384
Reported as:
Count of participants · Participants
Number of Participants in Steroid-free Crohn's Disease Activity Index (CDAI) Remission Over Time
ParticipantsAny Adalimumab
Week 021
Week 422
Week 822
Week 1220
Week 2421
Week 3622
Week 4822
Week 6021
Week 7219
Week 8420
Week 9620
Week 10818
Week 12016
Week 14415
Week 16813
Week 19211
Week 21610
Week 24010
Week 2648
Week 2886
Week 3124
Week 3362
Week 3601
SecondaryMean Change From Baseline in Pediatric Crohn's Disease Activity Index (PCDAI) Over Time

Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. The baseline value was defined as the last non-missing value on or before the date of the first dose of study drug in Study M06-806. Negative changes indicate reductions (improvement) in disease activity.

Time frame:
Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384
Reported as:
Mean · units on a scale
Mean Change From Baseline in Pediatric Crohn's Disease Activity Index (PCDAI) Over Time
units on a scaleAny Adalimumab
Week 0-29.95 ± 11.459
Week 4-30.15 ± 11.514
Week 8-30.7 ± 11.415
Week 12-29.19 ± 11.405
Week 24-29.84 ± 11.702
Week 36-30.89 ± 12.354
Week 48-30.73 ± 11.983
Week 60-32.78 ± 10.927
Week 72-31.15 ± 10.404
Week 84-32.94 ± 10.809
Week 96-31.14 ± 11.33
Week 108-33.54 ± 9.538
Week 120-33.36 ± 10.441
Week 144-34.38 ± 9.204
Week 168-32.57 ± 11.273
Week 192-33.00 ± 13.258
Week 216-31.95 ± 12.344
Week 240-34.18 ± 13.386
Week 264-35.00 ± 9.242
Week 288-35.95 ± 11.941
Week 312-33.19 ± 14.318
Week 336-35.23 ± 12.013
Week 360-38.75 ± 10.69
Week 384-46.25 ± 22.981
SecondaryMean Change From Baseline in Crohn's Disease Activity Index (CDAI) Over Time

The CDAI includes 8 variables: participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. Participants kept track of daily symptoms on a diary card, and the scores were summed for the week. Each item in the CDAI is assigned a specific weight, and the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. The scale for the score is as follows: \< 150 (remission), 150 - 219 (mildly active disease), 220 - 450 (moderately active disease) and \> 450 (severely active disease). A CDAI was calculated at each visit for those who were ≥ 13 years old at Study M06-806 entry. The baseline value was defined as the last non-missing value on or before the date of the first dose of study drug in Study M06-806. Negative changes indicate reductions (improvement) in disease activity.

Time frame:
Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384
Reported as:
Mean · units on a scale
Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) Over Time
units on a scaleAny Adalimumab
Week 0-160.8 ± 82.543
Week 4-159.9 ± 79.986
Week 8-164.45 ± 79.272
Week 12-151.34 ± 87.157
Week 24-161.51 ± 84.663
Week 36-173.55 ± 77.358
Week 48-162.08 ± 86.292
Week 60-168.27 ± 82.605
Week 72-165.4 ± 80.038
Week 84-172.68 ± 86.223
Week 96-168.3 ± 79.658
Week 108-171.63 ± 85.19
Week 120-179.14 ± 86.93
Week 144-181.53 ± 78.99
Week 168-175.05 ± 80.965
Week 192-172.42 ± 76.381
Week 216-173.13 ± 78.588
Week 240-184.46 ± 94.114
Week 264-186.42 ± 75.396
Week 288-197.11 ± 88.029
Week 312-199.00 ± 77.184
Week 336-240.33 ± 97.395
Week 360-224.86 ± 89.025
Week 384-458.00

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the time of study drug administration in Study M06-806 until 70 days after the last dose of study drug in Study M06-807 (up to 470 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Any Adalimumab0/100 (0%)48/100 (48%)98/100 (98%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventAny Adalimumab
CROHN'S DISEASEGastrointestinal disorders25/100
ANAL ABSCESSInfections and infestations3/100
ANAEMIABlood and lymphatic system disorders2/100
GASTRITISGastrointestinal disorders2/100
GASTROENTERITISInfections and infestations2/100
PNEUMONIAInfections and infestations2/100
SUBCUTANEOUS ABSCESSInfections and infestations2/100
LYMPHADENITISBlood and lymphatic system disorders1/100
VERTIGOEar and labyrinth disorders1/100
ABDOMINAL PAINGastrointestinal disorders1/100
Most frequent other events
Showing 10 of 84
Most frequent other events
EventAny Adalimumab
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations39/100
HEADACHENervous system disorders37/100
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations31/100
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders27/100
DIARRHOEAGastrointestinal disorders26/100
ABDOMINAL PAINGastrointestinal disorders24/100
CROHN'S DISEASEGastrointestinal disorders24/100
VOMITINGGastrointestinal disorders22/100
ARTHRALGIAMusculoskeletal and connective tissue disorders21/100
PYREXIAGeneral disorders20/100

Baseline characteristics

ITT Population: all participants who received ≥ 1 dose of adalimumab in Study M06-807 and also had ≥ 1 non-missing efficacy measurement during the study.

Age, Continuous
Age, Continuous(years)Any Adalimumab
Mean13.5 ± 2.5
Sex: Female, Male
Sex: Female, Male(Participants)Any Adalimumab
Female48
Male52
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Any Adalimumab
White93
Black3
Other2
Multi-race2
Body weight at Study M06-806 Baseline
Body weight at Study M06-806 Baseline(Participants)Any Adalimumab
< 40 kg38
≥ 40 kg62
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, Eichner S, Li Y, Reilly N, Thakkar RB, Robinson AM, Lazar A. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease. Inflamm Bowel Dis. 2017 Mar;23(3):453-460. doi: 10.1097/MIB.0000000000001021. PubMed 28129288 ↗
  • Horneff G, Seyger MMB, Arikan D, Kalabic J, Anderson JK, Lazar A, Williams DA, Wang C, Tarzynski-Potempa R, Hyams JS. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. J Pediatr. 2018 Oct;201:166-175.e3. doi: 10.1016/j.jpeds.2018.05.042. Epub 2018 Jul 25. PubMed 30054164 ↗
  • Ruemmele FM, Rosh J, Faubion WA, Dubinsky MC, Turner D, Lazar A, Eichner S, Maa JF, Alperovich G, Robinson AM, Hyams JS. Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis. 2018 Nov 9;12(10):1249-1254. doi: 10.1093/ecco-jcc/jjy087. PubMed 29939254 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Apr 2017 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 29, 2008
Start
May 1, 2008
Primary completionActual
Apr 4, 2017
CompletionActual
Apr 4, 2017
Results first posted
Apr 20, 2018
Last update
Jul 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00686374
Responsible party
Sponsor
First posted
May 29, 2008
Start date
May 1, 2008
Primary completion
Apr 4, 2017
Completion
Apr 4, 2017
Results posted
Apr 20, 2018
Last update
Jul 2, 2018

Study contacts

Andreas Lazar
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion